Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole
Authors:
Open Access
- 1 December 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 4 (12) , 1993-2001
Abstract
Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast density and serum estrogens at baseline, 6, and 12 months. The primary endpoint was change in contralateral percent breast density from baseline to 12 months. Secondary endpoints included change in serum estrone sulfate from baseline to 12 months. Fifty-four patients were accrued. At 12 months, compared with baseline, there was a nonstatistically significant reduction in breast density (mean change: −16%, 95% CI: −30 to 2, P = 0.08) and a significant reduction in estrone sulfate (mean change: −93%, 95% CI: −94 to −91, P < 0.001). Eighteen women achieved 20% or greater relative reduction in contralateral percent density at 12 months compared with baseline; however, no measured patient or disease characteristics distinguished these women from the overall population. Large trials are required to provide additional data on the relationship between aromatase inhibitors and breast density and, more importantly, whether observed changes in breast density correlate with meaningful disease-specific outcomes. Cancer Prev Res; 4(12); 1993–2001. ©2011 AACR.Keywords
This publication has 41 references indexed in Scilit:
- A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal womenBreast Cancer Research and Treatment, 2011
- Aromatase immunoreactivity is increased in mammographically dense regions of the breastBreast Cancer Research and Treatment, 2010
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 2010
- Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapyBreast Cancer Research and Treatment, 2010
- A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozoleBMC Cancer, 2010
- A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal womenBreast Cancer Research and Treatment, 2009
- Mammographic density. Measurement of mammographic densityBreast Cancer Research, 2008
- Reduction in proliferation with six months of letrozole in women on hormone replacement therapyBreast Cancer Research and Treatment, 2007
- Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized TrialJNCI: Journal of the National Cancer Institute, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002